Overview

Study Evaluating Sirolimus and Cyclosporine in Kidney Transplant Recipients

Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
To assess equivalence in the rates of functional graft survival at 12 months after transplantation in patients receiving continuous therapy with cyclosporine (CsA, Sandimmune, Neoral) and sirolimus versus induction with CsA and sirolimus followed by CsA elimination and concentration-controlled sirolimus.
Phase:
Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Cyclosporine
Cyclosporins
Everolimus
Sirolimus